Atherosclerosis
Volume 206, Issue 2 , Pages 351-352 , October 2009

A response to the letter regarding the pleiotropic effects of fluvastatin on acute inflammatory response and the role of MMP-9 in plaque destabilization and intraplaque hemorrhage

  • Kae Nakamura

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Japan
    • ,
  • Takeshi Sasaki

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Japan
    • Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, 1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan
    • ,
  • Xian Wu Cheng

      Affiliations

    • Department of Cardiovascular Research Medicine, Nagoya University Graduate School of Medicine, Japan
    • Department of Cardiology, Yanbian University Hospital, 119 Juzijie, Yanji, Jilin Province, 133000, China
    • ,
  • Masafumi Kuzuya

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 52 744 2364; fax: +81 52 744 2371.

Received 20 May 2009

References 

  1. Jackson CL, Johnson JL. Statin pleiotropism and atherosclerotic plaque rupture. Atherosclerosis 2009, doi:10.1016/j.atherosclerosis.2009.03.050, in press.
  2. Zadelaar S, Kleemann R, Verschuren L, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706–1721
  3. Li Z, Iwai M, Wu L, et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension. 2004;44:758–763
  4. Sata M, Nishimatsu H, Osuga J, et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension. 2004;43:1214–1220
  5. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115–121
  6. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 1997;79:84–87
  7. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002;135:284–292
  8. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4:1029–1036
  9. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50:50–55
  10. Orem C, Uydu HA, Yilmaz R, et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J. 2004;45:977–987
  11. Dangas G, Smith DA, Unger AH, et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000;83:688–692
  12. Nakamura K, Sasaki T, Cheng XW, Iguchi A, Sato K, Kuzuya M. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009, doi:10.1016/j.atherosclerosis.2009.02.014, in press.
  13. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900
  14. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379–387
  15. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008;102:209–217
  16. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006;116:59–69
  17. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005;102:15575–15580
  18. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004;109:1408–1414

PII: S0021-9150(09)00422-5

doi: 10.1016/j.atherosclerosis.2009.05.019

Atherosclerosis
Volume 206, Issue 2 , Pages 351-352 , October 2009

Article Tools